• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Sabina Signoretti, MD


  • Fay AP, Signoretti S, Choueiri TK.MET as a Target in Papillary Renal Cell Carcinoma.Clin Cancer Res. 2014 May 8.
  • González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP.Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition.Cancer Discovery. 2014 May 27.
  • Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates.J Clin Oncol. 2014 May 12.
  • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Cancer Discovery. 2014 May(5):546-53.
  • Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ.Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.Eur J Cancer. 2014 May;50(8):1531-40.
  • Xie H, Hanai JI, Ren JG, Kats L, Burgess K, Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, Wang X, Lorkiewicz PK, Schatzman S, Bousamra M, Lane AN, Higashi RM, Fan TW, Pandolfi PP, Sukhatme VP, Seth P.Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells.Cell Metab. 2014 Apr 9.
  • Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M.A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.EMBO Mol Med. 2014 Apr;6(4):519-38.
  • Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.Clin Cancer Res. 2014 Apr 1;20(7):1873-83.
  • Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, Signoretti S, Hu Y, Boyce FM, Gravdal K, Halvorsen OJ, Nalwoga H, Akslen LA, Harlow E, Watnick RS.GRK3 is essential for metastatic cells and promotes prostate tumor progression.Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1521-6.
  • Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S, Root DE, Tamayo P, Tsherniak A, Cheng SC, Tabak B, Jacobsen A, Hakimi AA, Schultz N, Ciriello G, Sander C, Hsieh JJ, Kaelin WG.SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.Cancer Cell. 2013 Dec 9;24(6):738-50.
  • Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC.Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.Cell. 2013 Nov 7;155(4):844-57.
  • Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.Clin Cancer Res. 2013 Sep 15;19(18):5218-26.
  • Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.Nat Genet. 2013 Jul;45(7):739-46.
  • Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.Nat Genet. 2013 Jul;45(7):747-55.
  • Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S.p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia.Proc Natl Acad Sci U S A. 2013 Apr 25.
  • Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD.Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.Cancer Res. 2013 Apr 22.
  • Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S.Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)☆.Urol Oncol. 2012 Nov 7.
  • Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, Cantley LC.Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3483-8.
  • Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.Br J Cancer. 2013 Feb 5;108(2):319-26.
  • Choueiri TK, Pomerantz MM, Signoretti S.Renal-cell carcinoma: a step closer to a new classification.Lancet Oncol. 2013 Feb;14(2):105-7.
  • Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.Cancer Discovery. 2013 Jan;3(1):44-51.
  • Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK.Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.Lancet Oncol. 2013 Jan;14(1):81-7.
  • Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, Sicinski P.The requirement for cyclin D function in tumor maintenance.Cancer Cell. 2012 Oct 16;22(4):438-51.
  • Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S.BRAF mutations in metanephric adenoma of the kidney.Eur Urol. 2012 Nov;62(5):917-22.
  • Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS.Identification of Luminal Breast Cancers that Establish a Tumor Supportive Macroenvironment Defined by Pro-Angiogenic Platelets and Bone Marrow Derived Cells.Cancer Discovery. 2012 Aug 15.
  • Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Collins M, Signoretti S, Torchilin V, Goldberg SN.Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model.Int J Hyperthermia. 2011;27(6):527-38.
  • Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS.Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.PLoS ONE. 2011;6(4):e19144.
  • Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM.Transgenic expression of polyoma virus middle T antigen in the mouse prostate gives rise to carcinoma.J Virol. 2011 Mar 16.
  • Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O.RET protein expression in papillary renal cell carcinoma.Urol Oncol. 2011 Mar 9.
  • Bernardi R, Papa A, Egia A, Coltella N, Teruya-Feldstein J, Signoretti S, Pandolfi PP.Pml represses tumour progression through inhibition of mTOR.EMBO Mol Med. 2011 Feb 17.
  • Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA.SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.Nature. 2011 Feb 10;470(7333):269-73.
  • Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S.Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.Am J Clin Pathol. 2010 Dec;134(6):873-9.
  • Yang W, Ahmed M, Elian M, Hady ES, Levchenko TS, Sawant RR, Signoretti S, Collins M, Torchilin VP, Goldberg SN.Do Liposomal Apoptotic Enhancers IncreaseTumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?.Radiology. 2010 Dec;257(3):685-96.
  • Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Kaelin WG, Signoretti S, DePinho RA.FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.Cancer Cell. 2010 Nov 16;18(5):472-84.
  • Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW.Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.Mol Cancer Ther. 2010 Oct;9(10):2793-802.
  • Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG.Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.Circulation. 2010 Sep 7;122(10):1004-16.
  • Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.BJU Int. 2010 Sep;106(6):772-8.
  • Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.Clin Cancer Res. 2010 Jul 15;16(14):3628-38.
  • Bhatt RS, Zhang L, Bullock A, Moreno K, Signoretti S, Atkins M, Sabbadini R, Mier J.Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC).AACR Proceedings 2010..
  • Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM.A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11002-7.
  • McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, French M, Regan MM, Atkins MB.The high-dose aldesleukin (HD IL-2) "Select" Trial in patients with metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings.;28(15S):345s.
  • Panka DJ, Collins M, Atkins MB, Signoretti S, Mier JW.Enhancement of efficacy of sorafenib and sunitinib with the HDM2 antagonist MI-319 in RCC tumor xenografts.AACR Proceedings..
  • Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, Rahmanuddin S, Levchenko T, Signoretti S, Spitz DR, Torchilin V, Goldberg SN.Liposomal Doxorubicin Increases Radiofrequency Ablation-induced Tumor Destruction by Increasing Cellular Oxidative and Nitrative Stress and Accelerating Apoptotic Pathways.Radiology. 2010 Apr;255(1):62-74.
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.The landscape of somatic copy-number alteration across human cancers.Nature. 2010 Feb 18;463(7283):899-905.
  • Hulick P, Zimmer M, Margulis V, Skates S, Hamel M, Dahl DM, Michaelson DM, Libermann T, Signoretti S, Carney W, Wood C, Iliopoulos O.Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity.Clin. Proteomics.;5(1):37-45.
  • Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO.Risk of bilateral renal cell cancer.J Clin Oncol. 2009 Aug 10;27(23):3737-41.
  • Bhatt R, Wang X, Zhang L, Bhasin M, Libermann T, O’Neil A, Signoretti S, Atkins M, Mier J, Goldberg SN.Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models.AACR Proceedings 2009..
  • Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA.Reciprocal effects of STAT5 and STAT3 in breast cancer.Mol Cancer Res. 2009 Jun;7(6):966-76.
  • Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S.p63 promotes cell survival through fatty acid synthase.PLoS ONE. 2009;4(6):e5877.
  • Schor-Bardach R,Alsop DC,Pedrosa I,Solazzo SA,Wang X,Marquis RP,Atkins MB,Regan M,Signoretti S,Lenkinski RE,Goldberg SN.Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?.Radiology. 2009 Jun;251(3):731-42.
  • Beroukhim R,Brunet JP,Di Napoli A,Mertz KD,Seeley A,Pires MM,Linhart D,Worrell RA,Moch H,Rubin MA,Sellers WR,Meyerson M,Linehan WM,Kaelin WG Jr,Signoretti S.Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney.Cancer Res. 2009 Jun 1;69(11):4674-4681.
  • Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.Cancer. 2009 May 15;115(10 Suppl):2247-51.
  • Di Napoli A, Signoretti S.Tissue biomarkers in renal cell carcinoma: issues and solutions.Cancer. 2009 May 15;115(10 Suppl):2290-7. Review.
  • Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S.Treatment selection for patients with metastatic renal cell carcinoma.Cancer. 2009 May 15;115(10 Suppl):2327-33. Review.
  • Migita T,Ruiz S,Fornari A,Fiorentino M,Priolo C,Zadra G,Inazuka F,Grisanzio C,Palescandolo E,Shin E,Fiore C,Xie W,Kung AL,Febbo PG,Subramanian A,Mucci L,Ma J,Signoretti S,Stampfer M,Hahn WC,Finn S,Loda M.Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.Journal of the National Cancer Institute. 2009 Apr 1;101(7):519-32.
  • Xie H,Valera VA,Merino MJ,Amato AM,Signoretti S,Linehan WM,Sukhatme VP,Seth P.LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.Mol Cancer Ther. 2009 Mar;8(3):626-35.
  • Majumder PK,Grisanzio C,O'Connell F,Barry M,Brito JM,Xu Q,Guney I,Berger R,Herman P,Bikoff R,Fedele G,Baek WK,Wang S,Ellwood-Yen K,Wu H,Sawyers CL,Signoretti S,Hahn WC,Loda M,Sellers WR.A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.Cancer Cell. 2008 Aug 12;14(2):146-55.
  • Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.Nature.;454:776-9.
  • Jia S,Liu Z,Zhang S,Liu P,Zhang L,Lee SH,Zhang J,Signoretti S,Loda M,Roberts TM,Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.Nature. 2008 Aug 7;454(7205):776-9.
  • Libermann TA, Bhasin M, Joseph MG, Signoretti S, Ernstoff MS, McDermott D, Atkins MB.Gene Expression Profiling Signatures Associated with RCC response to IL-2 Therapy.Proceedings of the 23rd ISBTC Meeting, J Immunotherapy ..
  • Sabir A,Schor-Bardach R,Wilcox CJ,Rahmanuddin S,Atkins MB,Kruskal JB,Signoretti S,Raptopoulos VD,Goldberg SN.Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.AJR Am J Roentgenol. 2008 Jul;191(1):133-9.
  • Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.Tissue-based research in kidney cancer: current challenges and future directions.Clin Cancer Res. 2008 Jun 15;14(12):3699-705. Review.
  • Regan MM, Brick AJ, Choueiri TK, Clement JM, Kwabi C, Shah K, Amato A, McDermott DF, Atkins MB, Signoretti S.Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy.J Clin Oncol..
  • Jaeger E, Waldman F, Roydasgupta R, Klatte T, McDermott DF, Signoretti S, Atkins MB, LaRochelle J, Belledegrun AS, Pantuck AJ.Array-based comparative genomic hybridization (CGH) identifies imbalances between interleukin-2 complete and non-responders.Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings.;26(15s):5043.
  • Signoretti S,Regan M,Atkins M.Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.BJU Int. 2008 Jun;101 Suppl 4:31-5. Review.
  • Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG Jr.VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400.Nat Cell Biol. 2008 Mar;10(3):361-9.
  • Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.Clin Genitourin Cancer. 2007 Sep;5(6):379-85.
  • Grisanzio C, Signoretti S.p63 in prostate biology and pathology.J Cell Biochem. 2008 Apr 1;103(5):1354-68. Review.
  • Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN.Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.Radiology. 2007 Aug;244(2):464-70.
  • Signoretti S, Loda M.Prostate stem cells: From development to cancer.Semin Cancer Biol. 2007 Jun;17(3):219-24. Review.
  • Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Regan M, Raptopoulos VD, Goldberg SM.Multislice CT Perfusion Imaging Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy.Radiology. 2007 Mar 01;In Press.
  • Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.
  • Zhan Q, Signoretti S, Whitaker-Menezes D, Friedman TM, Korngold R, Murphy GF.Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype.J Invest Dermatol. 2007 Jan;127(1):106-15.
  • De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS.A working group classification of focal prostate atrophy lesions.Am J Surg Pathol. 2006 Oct;30(10):1281-91.
  • Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M.Androgen-dependent regulation of Her-2/neu in prostate cancer cells.Cancer Res. 2006 Jun 1;66(11):5723-8.
  • Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN.Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.Radiology. 2006 Jul;240(1):82-9.
  • Signoretti S, Loda M.Defining cell lineages in the prostate epithelium.Cell Cycle. 2006 Jan;5(2):138-41.
  • Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M.p63 regulates commitment to the prostate cell lineage.Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11355-60.
  • Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC.Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10238-43.
  • Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S.Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res. 2005 May 15;11(10):3714-21.
  • Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN.Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.Radiology. 2005 May;235(2):469-77.
  • Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC.Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.Cancer Res. 2005 Apr 15;65(8):3044-8.
  • Horkan C, Dalal K, Coderre JA, Kiger JL, Dupuy DE, Signoretti S, Halpern EF, Goldberg SN.Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model.Radiology. 2005 Apr;235(1):81-8.
  • Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC.Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.Cancer Res. 2004 Dec 15;64(24):8867-75.
  • Atkins M, McDermott D, Mier J, Stanbridge E, Youmans A, Regan M., Febbo P Upton M, Lechpammer M, Signoretti S.Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy.J Clin Oncol.:In Press.
  • Murphy M, Carlson JA, Keough MP, Claffey KP, Signoretti S, Loda M.Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27.J Cutan Pathol. 2004 Aug;31(7):477-82.
  • Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M.The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.Cancer Cell. 2004 Mar;5(3):253-61.
  • Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M.Intermediate basal cells of the prostate: in vitro and in vivo characterization.Prostate. 2003 May 15;55(3):206-18.
  • Weinstein MH, Signoretti S, Loda M.Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.Mod Pathol. 2002 Dec;15(12):1302-8.
  • Lindeman N, Waltregny D, Signoretti S, Loda M.Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection.Diagn Mol Pathol. 2002 Dec;11(4):187-92.
  • Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA.Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation.Nature. 2002 Sep 12;419(6903):162-7.
  • Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M.Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.J Clin Invest. 2002 Sep;110(5):633-41.
  • Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K.Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia.Oncogene. 2002 Jun 13;21(26):4099-107.
  • DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M.Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line.Cancer Res. 2002 Jan 1;62(1):89-98.
  • Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, Merlino G, DePinho RA.Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.Mol Cell Biol. 2002 Jan;22(2):635-43.